Utility of a weight-based heparin nomogram for patients with acute coronary syndromes

Internal Medicine Journal

Volumn 33, Issue 1-2, 2003, Pages 18-25

  Zimmermann, Anthony T ^a   Jeffries, W S ^b   McElroy, H ^c   Horowitz, J D ^c  

^a REPATRIATION GENERAL HOSPITAL   (Australia)

^b LYELL MCEWIN HOSPITAL   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

Activated partial thromboplastin time (APTT); Acute coronary syndrome; Heparin; Weight based nomogram

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; ANTICOAGULATION; ARTICLE; BODY WEIGHT; DOSE CALCULATION; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; TITRIMETRY;

AGED; ANGINA, UNSTABLE; ANTICOAGULANTS; BODY WEIGHT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; TREATMENT OUTCOME;

EID: 0037283310     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1445-5994.2002.00297.x     Document Type: Article

References (25)

1. Theroux P, Ouimet H, McCans J, Latour JG, Joly P, Levy G et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11.
2. Theroux P, Waters D, Lam J, Juneau M, McCans J. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141-5.
3. Neri Serneri GG, Modesti PA, Gensini GF, Branzi A, Melandri G, Poggesi L et al. Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Eporine Sottocutanea Nell' Angina Instobile (SESAIR) Refrattorie Group. Lancet 1995; 345: 1201-4.
4. Cohen M, Adams PC, Parry G, Xiong J, Chamberlain D, Wieczorek I et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in non prior aspirin users: primary end points analysis from the ATACS (Antithrombotic Therapy in Acute Coronary Syndromes) trial. Circulation 1994; 89: 81-8.
5. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina: a meta-analysis. JAMA 1996; 276: 811-5.
6. The RISC group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336: 827-30.
7. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarcto Miocardico. GISSI - 2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
8. The International Study Group. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990; 336: 71-5.
9. The Third International Study of Infarct Survival (ISIS-3) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41299 cased of suspected acute myocardial infarction. Lancet 1992; 339: 753-70.
10. The Global Utilisation of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) Investigators. An international randomised trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-82.
11. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52.
12. Antman EM, McCabe CH, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S et al. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction: results of the TIMI 11B (Thrombolysis In Myocardial Infarction) trial. Circulation 1999; 100: 1593-601.
13. Armstrong PW. Heparin in acute coronary disease - requiem for a heavyweight? N Engl J Med 1997; 337: 492-4.
14. The Platelet Receptor inhibition in Ischaemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
15. Ivey LM, Thom JY, Baker RI. Single or duplicate analysis for automated prothrombin time and activated partial thromboplastin time? Pathology 1997; 29: 67-71.
16. Altman DG. Practical Statistics for Medical Research. London: Chapman and Hall; 1991.
17. Hochman SJ, Andreas UW, Gavrila D, Sim MJ, Sanjay M, Palazzo AM et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J 1999; 138: 313-8.
18. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight based heparin dosing nomogram compared with a standard care nomogram. Ann Intern Med 1993; 119: 874-81.
19. White RH, Zhou H, Woo L, Mungall D. Effect of weight, sex, age, clinical diagnosis and thromboplastin reagent on steady-state intravenous heparin requirements. Arch Intern Med 1997; 157: 2468-72.
20. Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO - I Trial. Circulation 1996; 93: 870-8.
21. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
22. Cruickshank MK, Levine MN, Hirsh J, Roberts R, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151: 333-7.
23. Salamonson Y. The ineffectiveness of a non-weight-based heparin regimen in achieving therapeutic activated partial thromboplastin time (APTT) in acute coronary syndromes. Aust Crit Care 2000; 13: 128-33.
24. Duffy M, Bau S, Kelly AM, Rosengarten P. Is a standard regime for anticoagulation with heparin in unstable angina adequate? Aust NZ J Med 1997; 27: 665-8.
25. Mungall D, Lord M, Cason S, Treadwell P, Williams D, Tedrick D. Developing and testing a system to improve the quality of heparin anticoagulation in patients with acute cardiac syndromes. Am J Cardiol 1998; 82: 574-9.